Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls

Paulo Gustavo Kotze, Subrata Ghosh, Willem A Bemelman, Remo Panaccione

Research output: Contribution to journalArticlepeer-review

7 Citations (Scopus)
111 Downloads (Pure)

Abstract

Recent advances in medical and surgical therapy were achieved during the last two decades in the management of Crohn's disease (CD). Anti-tumor necrosis factor (anti-TNF) agents are widely used worldwide. However, a significant proportion of patients still need surgical resections. The impact of previous exposure to these agents on the perioperative and postoperative outcomes is still controversial. In this critical review, we aimed to position the strategy of intentional preoperative use of anti-TNF agents in the management of CD. The indications and contraindications for this strategy are detailed, and despite scarce evidence, the possible advantages and disadvantages of the intentional use of anti-TNF agents before abdominal surgery in CD are discussed.

Original languageEnglish
Pages (from-to)160-165
Number of pages6
JournalIntestinal Research
Volume15
Issue number2
DOIs
Publication statusPublished - Apr 2017

Keywords

  • Crohn disease
  • Tumor necrosis factor-alpha
  • Preoperative care

Fingerprint

Dive into the research topics of 'Preoperative use of anti-tumor necrosis factor therapy in Crohn's disease: promises and pitfalls'. Together they form a unique fingerprint.

Cite this